HUDDINGE, Sweden, February 8, 2012 /PRNewswire/ -- Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, announces

Persons who have tested positive for herpes simplex virus type 2 (HSV-2) but do not have symptoms or genital lesions still experience virus shedding during subclinical (without clinical manifestations) episodes, suggesting a high risk of transmission from persons with unrecognized HSV-2 infection.

HUDDINGE, Sweden, March 1, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese(TM) in the United States. Xerese(TM) is the first topical combination product of five per cent acyclovir and one per cent hydrocortisone in a unique cream vehicle for the treatment of recurrent herpes simplex labialis.

RESEARCH TRIANGLE PARK, N.C., Nov.

BOSTON and RESEARCH TRIANGLE PARK, N.C., Sept.